Integration of Urine Proteomic and Metabolomic Profiling Reveals Novel Insights Into Neuroinflammation in Autism Spectrum Disorder

Wenlong Liu 1, Liming Li 2, Xiaochun Xia 2, Xulan Zhou 2, Yukai Du 3, Zhaoqing Yin 4 and Juan Wang 2*

1 Department of Child Development and Behavior, School of Medicine, Women and Children’s Hospital, Xiamen University, Xiamen, China, 2 Department of Public Health and Medical Technology, Xiamen Medical College, Xiamen, China, 3 Department of Maternal and Child Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 4 Division of Neonatology, The People’s Hospital of Dehong Autonomous Prefecture, Mangshi, China

Autism spectrum disorder (ASD) comprises a group of neurodevelopmental disorders whose etiology and pathogenesis are not fully understood. To gain insight into the molecular basis of ASD, we performed comparative integrated proteomic and metabolomic analyses of urine samples from children diagnosed with ASD and healthy children. All 160 samples underwent proteomics analysis and 60 were analyzed by liquid chromatography-mass spectrometry to obtain metabolite profiles. We identified 77 differentially expressed proteins (DEPs; 21 downregulated and 56 upregulated) and 277 differentially expressed metabolites; 31 of the DEPs including glutathione, leukocyte antigens, glycoproteins, neural adhesion factors, and immunoglobulins, have been implicated in neuroinflammation. The proteomic analysis also revealed 8 signaling pathways that were significantly dysregulated in ASD patients; 3 of these (transendothelial leukocyte migration, antigen processing and presentation, and graft vs. host disease) were associated with the neuroimmune response. The metabolism of tryptophan, which is also related to the neuroimmune response, has been found to play a potential role in ASD. Integrated proteome and metabolome analysis showed that 6 signaling pathways were significantly enriched in ASD patients, 3 of which were correlated with impaired neuroinflammation (glutathione metabolism, metabolism of xenobiotics by cytochrome P450 and transendothelial migration of leukocyte). We also found a correlation between prostaglandin (PG) E2 levels and the inflammatory response in ASD. These results underscore the prominent role of the neuroimmune response in ASD and provide potential biomarkers that can be used for diagnosis or as targets for early intervention.

Keywords: autism spectrum disorder, proteomics, metabolomics, integrated analysis, urine, neuroinflammation
INTRODUCTION

Autism spectrum disorder (ASD) comprises a group of neurodevelopmental disorders clinically characterized by deficits in social interaction and communication, and stereotyped behaviors (1). The prevalence of ASD in the United States increased from 0.67% in 2000 to 1.85% in 2016 (2); in China, the prevalence is 7 in 1,000 (3). The etiology of ASD involves a combination of genetic, epigenetic, and environmental factors and is not fully understood.

Immune system dysregulation is a risk factor for the development and progression of ASD (4, 5), as evidenced by an aberrant cytokine response, abnormal numbers of immune cells, neuroinflammation, dysfunction of the adaptive and innate immune systems, and altered immunoglobulin levels in individuals with ASD. The pro-inflammatory factor Osteopontin (OPN) was found to be upregulated in ASD patients, which was significantly correlated with autism severity (6). In addition, children with ASD may present with several distinct immune subphenotypes that are correlated with the degree of behavioral impairment (7). Maternal immune activation—especially involving interleukin (IL)-17—was found to be a major contributor to neurodevelopmental abnormalities in a mouse model of ASD (8). These findings suggest a close association between neuroinflammation and ASD pathogenesis. On the other hand, the behavioral symptoms of children with ASD were shown to improve with fever (9), implying that inflammation has a beneficial role in ASD. Thus, the relationship between neuroinflammation and ASD remains to be elucidated.

High-throughput -omics technologies have provided molecular-level insights into normal physiology as well as into disease states, including ASD. Proteomic analysis revealed 41 proteins related to endoplasmic reticulum stress, unfolded protein response, acute-phase response, inflammatory response, and endocytosis with altered levels in peripheral blood mononuclear cells of patients with ASD compared with the control subjects (10). Using a proteomic approach, another study identified 2 brain regions with dysregulated glutamate receptor signaling, glutathione (GSH)-mediated detoxification, and fatty acid oxidation in children with ASD (11). Metabolomic studies have shown that the levels of metabolites associated with abnormal amino acid metabolism, oxidative stress, and gut microbiome were altered in children with ASD (12, 13). It was recently reported that 3 metabolic pathways (pyrimidine, ubiquinone, and vitamin K metabolism) were perturbed in children with ASD, with a panel of central nervous system biomarkers (9-hexadecenoylcarnitine [C16:1] and phosphatidylcholine [PC ae-C36:1]) found by metabolomic analysis (14). Integrated analyses of -omics data have identified potential biomarkers and revealed their interrelationships (15–18). However, to date, there have been no studies that have applied a combination of metabolomic and proteomic approaches to the investigation of ASD etiology.

In this study, we performed comparative proteomic and metabolic profiling of urine samples from children with ASD and normal children in order to investigate the contribution of neuroinflammatory mechanisms to ASD pathogenesis. Our results provide insight into the molecular basis of ASD and biomarkers that can support diagnosis or serve as targets for therapeutic interventions.

MATERIALS AND METHODS

Ethics Approval

This study was conducted in accordance with the 1965 Declaration of Helsinki and its later amendments. The study protocol was approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (Hubei, China) (approval no: IORG0003571). Written, informed consent was obtained from the parents of participants.

Study Participants and Sample Collection

A total of 160 Chinese children including 80 with ASD and 80 with typical development (TD), were enrolled in the study. Children with ASD (age range: 2–7 years old) without other systematic diseases or neurodevelopmental disorders were recruited from Xiamen Women and Children's Hospital, Xiamen, Fujian, China and evaluated by a neuropsychiatrist specializing in autism. The diagnosis of ASD was made based on the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (19). Gender- and age-matched children with TD were recruited from schools in Xiamen.

Midstream urine samples (50 ml) were collected in sterile tubes in the morning and immediately placed on dry ice to prevent bacterial growth. After thawing for 30 min at room temperature, the samples were centrifuged at 3,000 × g for 15 min at 4°C and stored at −80°C until use.

Capillary Flow Data-Independent Acquisition–Based Proteomic Analysis

A 5-ml urine sample was obtained from each participant and 10 samples were combined for proteomic analysis. A total of 16 pooled samples (8 each from patients with ASD and subjects with TD) were analyzed.

DIA proteomic analysis was carried out as described previously (20–22). High-pH reverse-phase separation was conducted using a liquid-phase system (LC-20AB; Shimadzu, Tokyo, Japan). The elution peak was monitored at 214 nm and one component was collected every minute. The sample was combined with the elution peak of the chromatogram to obtain 10 components and then freeze-dried.

Dried peptide samples were reconstituted and centrifuged and then separated using an ultrahigh-pressure liquid chromatography (UPLC) system (Ultimate 3000; Thermo Fisher Scientific, Waltham, MA, USA). Peptides were separated with mobile phase A (2% acetonitrile+0.1% formic acid) and mobile phase B (98% acetonitrile+0.1% formic acid) at a flow rate of 500 nl/min using the following program: 5% phase B for the first 5 min, phase B (5–35%) from 5 to 160 min, phase B (35–80%) from 160 to 170 min, 80% phase B from 170 to 175 min, and 5% phase B in the final 5 min. The peptides separated by the liquid phase were sprayed through a nano-electrospray ionization source into a tandem mass spectrometer (Q Exactive...
Metabolite Profiling
A total of 60 urine samples (30 individual ASD samples and TD samples) were used for metabolic analysis, which was performed as described previously (23–25). Urine samples were slowly thawed at 4°C, and 100 µl of the sample was combined with 300 µl of precooled methanol and mixed by vortexing for 1 min. The mixture was stored at −20°C for 2 h and then centrifuged at 4,000 × g at 4°C for 30 min. A 250-µl aliquot of supernatant from each sample was set aside for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. A quality control (QC) sample was prepared by mixing equal volumes of each sample.

A UPLC system (2777C; Waters, Milford, MA, USA) equipped with an Acquity UPLC HSS T3 column (100 × 2.1 mm, 1.8 µm; Waters) was used to separate urine metabolites. Mobile phase A was water and 0.1% formic acid, while mobile phase B was acetonitrile and 0.1% formic acid. The gradient elution program was as follows: 0–1 min, 99% A; 1–3 min, 85–99% A; 3–6 min, 50–85% A; 6–9 min, 50–95% A; 9–10 min, 5% A; and 10–12 min, 1% A. The injection volume for each sample was 10 µl, and the flow rate was set to 0.4 ml/min.

A high-resolution tandem mass spectrometer (Xevo G2 XS QTOF; Waters) was used to detect metabolites. Samples were analyzed in positive and negative ion modes. The capillary voltage and sampling cone voltage were set to 3.0 kV and 40.0 V, respectively, in positive ion mode and to 2.0 kV and 40.0 V, respectively, in negative ion mode. The time-of-flight mass range was from 50 to 1,200 Da and the scan time was 0.2 s. For MS/MS detection, all the precursors were fragmented using 20–40 eV with a scan time of 0.2 s. To evaluate the stability of the LC-MS/MS system during acquisition, a QC sample was obtained every 10 samples.

For metabolomic analysis, raw data files were created using Progenesis QI v2.2 software (Waters) for peak alignment and selection. Data were normalized with the projected quasi-Newton method (26), and low-quality ions with relative standard deviation (RSD) > 30% were filtered out. p-values were adjusted with the Benjamini–Hochberg method for multiple hypothesis testing, and the FDR was limited to 0.05.

Metabolomic data were mean-centered, pareto-scaled, and analyzed by principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA). The quality of the models was evaluated with the relevant R² and Q² values (27). The variable influence in projection (VIP) value in the PLS-DA model was calculated to determine its contribution to the classification. Metabolites with VIP > 1.0 were evaluated with the Student’s t-test at the univariate level to determine the significance of each metabolite. A corrected P-value (q value) < 0.05 was considered statistically significant. Log2 fold change was used to determine how the selected metabolites differed between the ASD and TD groups.

The Human Metabolome Database and KEGG database were used to confirm candidate differentially expressed metabolites (DEMs). Pathway analyses of DEMs were performed using MetaboAnalyst v5.0 (www.metaboanalyst.ca) (28).

Integrated Proteomic and Metabolomic Data Analyses
MetaboAnalyst v5.0 was used to perform integrated pathway analyses of DEPs and DEMs (29). To integrate the pathway data, DEPs and DEMs were simultaneously projected into pathways in the KEGG database.

Statistical Analyses
Statistical analyses were carried out using SPSS v19.0 (IBM, Armonk, NY, USA). Data are reported as the mean ± SD. Normally distributed data were analyzed with the Student’s t-test to assess the significance of differences between the ASD and TD groups. A p < 0.05 was considered statistically significant.

RESULTS
Demographics of the Study Population
The study population comprised 80 children with ASD and 80 with TD. The demographic characteristics of the participants are presented in Table 1. There was no significant difference in age or sex ratio between groups (P > 0.05).

| Characteristics | Groups | P-value |
|-----------------|--------|---------|
|                 | TD(n = 80) | ASD(n = 80) |
| Agea (means ± SD, years) | 4.51 ± 1.03 | 4.73 ± 1.21 | 0.234 |
| Genderb | Male | 53 | 64 | 0.074 |
|          | Female | 27 | 16 |

TD, typically developing group; ASD, autism spectrum disorders; SD, Standard Deviation.
a Analyzed using the Student’s t-test.
b Analyzed using the Chi-squared test.
TABLE 2 | List of differentially expressed proteins.

| Asscession no. | Protein descriptive | Abbreviation | Log2FC | p-Value |
|----------------|---------------------|--------------|--------|---------|
| P10451         | Osteopontin isoform OPN-a prephosursor | OPN           | 1.238  | 0.038   |
| Q9UHF5         | Interleukin-17B isoform 1 precursor | IL17B         | 1.027  | 0.006   |
| Q7LDX0         | TLR4 Interactor with leucine rich repeats precursor | TRIL          | 1.052  | 0.024   |
| A0A075BB65     | Immunoglobulin kappa variable 1–27   | IGKV1-27      | 1.128  | 0.049   |
| A0A0C4DH72     | Immunoglobulin kappa variable 1–6    | IGKV1-6       | 1.234  | 0.034   |
| P01593         | Immunoglobulin kappa variable 1–33   | IGKV1D-33     | 1.017  | 0.013   |
| P01703         | Immunoglobulin lambda variable 1–40  | IGLYV1-40     | 2.112  | 0.024   |
| P01705         | Immunoglobulin lambda, partial        | IGLYV2-23     | 1.156  | 0.040   |
| P01715         | Immunoglobulin lambda variable 3–1   | IGLYV3-1      | 1.451  | 0.015   |
| P01601         | Immunoglobulin variable region VK-NHL104 | IGKV1D-16     | 1.103  | 0.043   |
| Q9NPY3         | Complement component C1q receptor     | CD93          | 1.033  | 0.023   |
| P10314         | HLA class I histocompatibility antigen, A-32 alpha chain | HLA-A         | 1.168  | 0.012   |
| P13284         | Gamma-interferon inducible lysosomal thiol reductase | IFI30         | 1.138  | 0.037   |
| P19320         | Vascular cell adhesion protein 1 isoform 1 precursor | VCAM1         | 1.437  | 0.003   |
| P13591         | Neural cell adhesion molecule 1 isoform 2 precursor | NCAM1         | 2.087  | 0.008   |
| Q13740         | CD166 antigen isoform 1 precursor     | ALCAM1        | 1.004  | 0.005   |
| Q9UW4          | Guanine nucleotide exchange factor VAV3 isoform 1 | VAV3          | 3.626  | 0.035   |
| Q75309         | Cadherin-16 isoform 1 precursor       | CDH16         | 1.132  | 0.031   |
| P33151         | Cadherin-5, type 2 preproprotein variant, partial | CDH5          | 2.146  | 0.003   |
| P14174         | Macrophage migration inhibitory factor | MIF           | 1.427  | 0.008   |
| P02763         | Alpha-1-acid glycoprotein 1         | ORM1          | 1.397  | 0.016   |
| P19652         | Alpha-1-acid glycoprotein 2 precursor | ORM2          | 1.325  | 0.011   |
| P25311         | Zinc-alpha-2-glycoprotein precursor  | A2GPI1        | 1.139  | 0.007   |
| P02765         | Alpha-2-HS-glycoprotein isoform 2 preproprotein | AHS2G         | 1.111  | 0.011   |
| P02750         | Leucine-rich alpha-2-glycoprotein precursor | LRG1          | 1.396  | 0.046   |
| P07359         | Platelet glycoprotein lb alpha chain precursor | GP1BA         | 1.338  | 0.016   |
| Q00468         | Agrin                             | AGRN          | 1.006  | 0.015   |
| P51170         | Amiloride-sensitive sodium channel subunit gamma | SCNN1G        | 1.641  | 0.012   |
| P35318         | ADM precursor                      | ADM           | 1.305  | 0.025   |
| P61769         | Beta-2-microglobulin               | B2M           | 1.017  | 0.010   |
| P06396         | Gelosin                           | GSN           | 1.046  | 0.011   |
| P01258         | Calcitonin isoform CT preproprotein | CALCA         | 1.066  | 0.015   |
| P10645         | Chromogranin-A isoform 1 preproprotein | CHGA          | 1.632  | 0.032   |
| Q9BY43         | Chromatin-modifying protein 4a     | CHMP4A        | 1.026  | 0.038   |
| Q9H6B4         | CXADR-like membrane protein        | CLMP          | 1.030  | 0.019   |
| Q06PD2         | Discoidin, CUB and LCLL domain-containing protein 2 precursor | DCBLD2       | 1.194  | 0.013   |
| P35555         | Fibrillin                          | FBN           | 1.985  | 0.031   |
| Q08830         | Fibrinogen-like protein 1 precursor | FOL1          | 1.753  | 0.028   |
| P07093         | Gla-derived nexitin isoform a precursor | SERPINE2     | 1.194  | 0.031   |
| P16520         | Guanine nucleotide-binding protein G(i)/G(S)/G(T) subunit beta-3 isoform 1 | GNB3         | 1.618  | 0.037   |
| P24593         | Insulin-like growth factor-binding protein 5 precursor | IGFBP5       | 1.601  | 0.010   |
| Q96MU8         | Kremen protein 1                   | KREMEN1       | 1.181  | 0.049   |
| Q9Y5K2         | Kalikrein-4                        | KLK4          | 1.413  | 0.009   |
| Q6UX15         | Laylin isoform 1 precursor         | LAYN          | 1.015  | 0.013   |
| Q13449         | Limbic system-associated membrane protein isoform 1 preproprotein | LSAMP        | 1.048  | 0.043   |
| Q03897         | Lysyl oxidase homolog 1 preproprotein | LOXL1         | 1.532  | 0.013   |
| Q16819         | Meprin A subunit alpha precursor   | MEP1A         | 1.151  | 0.020   |
| P15586         | N-acetylglucosamine-6-sulfatase precursor | GNS          | 1.012  | 0.009   |
| P34059         | N-acetylgalactosamine-6-sulfatase isoform 1 precursor | GALNS        | 1.322  | 0.012   |
| Q8UX8B8        | Peptidase inhibitor 16 precursor  | PI16          | 1.420  | 0.009   |

(Continued)
TABLE 2 | Continued

| Assenion no. | Protein descriptive | Abbreviation | Log2FC | p-Value |
|--------------|---------------------|--------------|--------|---------|
| Q6S96        | Phosphatidylethanolamine-binding protein 4 | PEBP4        | 1.043  | 0.031   |
| Q3103        | Secreted phosphoprotein 24 precursor | SPP2         | 1.043  | 0.033   |
| Q9NY72       | Sodium channel subunit beta-3 precursor | SCN3B        | 1.159  | 0.003   |
| Q85Y3X3      | Sorting nexin-5 isoform a | SNX5         | 1.050  | 0.028   |
| P11684       | Uteroglobin precursor | SCGB1A1      | 1.973  | 0.005   |
| Q8VY21       | VPS10-domain-containing receptor SorCS1 isofrom a precursor | SORCS1      | 1.495  | 0.046   |
| P26842       | CD27 antigen | CD27         | −1.758 | 0.043   |
| P56975       | Pro-neuregulin-3, membrane-bound isofrom X10 | NRG3        | −3.155 | 0.022   |
| P18206       | Vinculin isofrom meta-VCL | VCL         | −1.421 | 0.009   |
| P21266       | Glutathione S-transferase Mu 3 | GSTM3 | −1.132 | 0.031   |
| Q6P531       | Gamma-glutamyltransferase 6 isofrom | GGT6        | −1.714 | 0.016   |
| P04745       | Alpha-amylase 1 | AMY1A | −1.064 | 0.020   |
| P19961       | Alpha-amylase 2B | AMY2B | −1.048 | 0.003   |
| Q16706       | Alpha-mannosidase 2 | MAN2A1 | −1.092 | 0.021   |
| P54802       | Alpha-N-acetylglucosaminidase precursor | NAGLU        | −1.277 | 0.011   |
| P25705       | ATP synthase isofrom alpha, mitochondrial isofrom a precursor | ATP5F1A | −3.722 | 0.005   |
| Q53H82       | Endoribonuclease LACTB2 | LACTB2 | −2.413 | 0.017   |
| P06744       | Glucose-6-phosphate isomerase isofrom 3 | GPI        | −2.230 | 0.003   |
| P00461       | Golgi integral membrane protein 4 isofrom 1 | GOLM4       | −1.775 | 0.015   |
| P04746       | Pancreatic alpha-amylase isofrom | AMY2A | −1.084 | 0.012   |
| Q6B7Y2       | Plasma alpha-L-fucosidase isofrom | FUC2A | −1.698 | 0.012   |
| Q9UQ80       | Proliferation-associated protein 2G4 | PA2G4 | −2.631 | 0.041   |
| Q6KPH2       | Serine/threonine-protein kinase ULK3 | ULK3 | −1.996 | 0.031   |
| Q13813       | Spectrin alpha chain, non-erythrocytic 1 isofrom X6 | SPTAN1 | −2.467 | 0.048   |
| P04066       | Tissue alpha-L-fucosidase isofrom | FUC1A | −1.485 | 0.004   |
| P18059       | Unconventional myosin-1c | MYO1C | −1.126 | 0.043   |
| P30050       | 60S ribosomal protein L12 | RPL12 | −3.738 | 0.046   |

▲ up-regulated; ▼ down-regulated.

Proteomic Profiling
A total of 2,700 proteins were identified using a DIA-based proteomic method. There were 77 DEPs (56 upregulated and 21 downregulated) between the ASD and TD groups (Table 2 and Supplementary Figure 1). Of these, 31 (40%) were associated with neuroinflammation (Figure 1), including 26 that were upregulated and 5 that were downregulated in the ASD group compared with the TD group. Immunoglobulins accounted for the largest proportion of these proteins; the remaining proteins were neural adhesion factors, glycoproteins, leukocyte antigens, and GSH.

Protein Enrichment Analysis
We performed a functional enrichment analysis of DEPs and identified significantly enriched terms (Figure 2). There were 16, 28, and 131 significant terms in the GO categories of cellular component, molecular function, and biological process, respectively (P < 0.05). The most enriched terms in the cellular component category were secretory vesicle and secretory granule, whereas the most enriched molecular function term was molecular function regulator. The top-ranked enriched terms in the biological process category were multicellular organism process, developmental process, anatomical structure development, multicellular organism development, and immune system process. Among the significantly enriched biological process terms, 38 were related to immune response (Supplementary Table 1) including immune system process, immune response, and immune effector process, among others.

The KEGG pathways associated with the DEPs identified in the ASD group are shown in Figure 3. In total, eight pathways were significantly enriched including starch and sucrose metabolism, carbohydrate digestion and absorption, taste transduction, glycosaminoglycan degradation, leukocyte transendothelial migration, antigen processing and presentation, graft-vs.-host disease, and neuroactive ligand-receptor interaction (Figure 3A and Table 3). Notably, 3 of the 8 pathways (leukocyte transendothelial migration, antigen processing and presentation, and graft-vs.-host disease) were associated with the immune response. In addition, the expression of DEPs related to starch and sucrose metabolism and carbohydrate digestion and absorption was decreased whereas that of DEPs involved in taste transduction, antigen processing and presentation, graft-vs.-host disease, and neuroactive ligand-receptor interaction was increased (Figure 3B).
Metabolomic Analysis

We detected 7,667 and 9,837 features in positive and negative ion modes, respectively. The number of features in QC samples with RSD $\leq$ 30% was 6,674 in positive ion mode and 8,202 in negative ion mode (87.05 and 83.38%, respectively). The results of PCA showed that the pooled QC sample was clustered in positive and negative ion modes (Supplementary Figure 2). The PLS-DA revealed a significant difference between the ASD and TD groups (Figure 4). The reliability of the PLS-DA model was assessed by monitoring the goodness of fit ($R^2$) and predictive ability ($Q^2$), which were 0.811 and 0.468, respectively, in positive ion mode and 0.799 and 0.420, respectively, in negative ion mode. These results suggested that the stability and reproducibility of the models were sufficient to resolve DEMs between children with ASD and TD.

A total of 168 metabolites were differentially expressed (VIP $\geq$ 1.0 and $q < 0.05$) in positive ion mode (Supplementary Table 2) including 105 that were upregulated and 63 that were downregulated in the ASD group compared to the TD group. In negative ion mode, 109 metabolites were significantly altered (VIP $\geq$ 1.0 and $q < 0.05$) including 73 that were upregulated and 36 that were downregulated in the ASD group compared to the TD group (Supplementary Table 3).

Metabolite Enrichment Analysis

We examined pathways corresponding to significantly altered metabolites in ASD using MetaboAnalyst according to FDR $<0.05$ and an impact value $>0.1$. Four processes—namely, phenylalanine metabolism, vitamin B6 metabolism, tryptophan metabolism, and pentose and glucuronate interconversions—were markedly enriched in positive ion mode in the ASD group compared with the TD group (Figure 5A). Only 1 pathway, pentose and glucuronate interconversions, was significantly enriched in negative ion mode (Figure 5B).
Integrated Analysis of Proteome and Metabolome Data

To examine global changes in protein and metabolite profiles between the ASD and TD groups, we mapped DEPs and DEMs and extracted pathways containing both proteins and metabolites using the "Joint Pathway Analysis" tool in MetaboAnalyst v5.0. The Venn diagram revealed 31 metabolic pathways in positive ion mode and 24 in negative ion mode that were associated with the DEPs and DEMs (Figure 6). Integrated proteomic and metabolomic analyses showed 6 altered pathways in the ASD group compared with the TD group including GSH metabolism, glycolysis or gluconeogenesis, metabolism of xenobiotics by cytochrome P450, glycosaminoglycan degradation, starch and sucrose metabolism, and leukocyte transendothelial migration (Figure 7). Three of these pathways were correlated with dysregulation of neuroinflammation—namely, GSH metabolism, metabolism of xenobiotics by cytochrome P450, and leukocyte transendothelial migration.

DISCUSSION

This study investigated the molecular basis of ASD pathogenesis with a combined proteomic and metabolomic approach. Immune dysfunction is thought to be involved in the etiology of ASD (4, 5). In this study, 40% of DEPs identified by the proteomic analysis were related to neuroinflammation and 3 associated protein pathways were related to the immune response. In the integrated proteomics and metabolomics analysis, 3 pathways were found to be correlated with dysregulation of neuroinflammation. These results provide theoretical evidence of the role of neuroinflammation in ASD pathology.

Children with ASD often exhibit abnormal redox signaling, especially in GSH metabolism (30). Synergistic and antagonistic interactions between glutamate and GSH can result in neuronal dysfunction. Chen et al. (31) revealed that 18 oxidative stress-related markers were dysregulated in the blood of children with ASD. These 18 oxidative stress markers included glutathione metabolism, transmethylation cycle and transsulfuration pathways, vitamins, and trace elements. In this study, the integrated analysis showed that GSH metabolism was significantly altered in ASD, which was accompanied by decreased expression of GSH S-transferase Mu 3 (GSTM3) and γ-glutamyltransferase 6 isoform (CGT6) in the ASD group. A previous study reported an imbalance in the GSH/GSSH disulfide ratio and depletion of GSH in children with ASD, implying that the GSH system plays a protective role in this disorder (32). GSTM3 is an enzyme that detoxifies electrophilic compounds via the conjugation of GSH (33). The decrease in GSTM3 expression observed in the ASD group in our study suggests that the protective effect of GSH is diminished in ASD. Immune cell dysfunction can lead to the release of proinflammatory mediators...
such as cytokines, chemokines, and reactive oxygen species (ROS), which are thought to contribute to the pathogenesis of ASD (5, 34, 35). Some inflammatory cytokines and oxidative stress parameters were shown to be positively associated with impaired behavioral patterns in patients with ASD, indicating that antioxidants play an essential role in the modulation of inflammatory potential (36, 37).

Our results showed that OPN, interleukin (IL)-17B, and toll-like receptor 4 interactor with leucine-rich repeats precursor (TRIL) were upregulated in the ASD group. OPN is a proinflammatory cytokine that plays a key role in inflammation, biomineralization, cellular viability, cancer, and diabetes via distinct mechanisms (38). OPN can increase the secretion level of interleukin (IL)-10, interleukin (IL)-12, and nuclear factor (NF)-κB and stimulate IL-17 production, which was shown to be correlated with ASD severity (5). It was also reported that IL-17A/IL-17R activation plays an important role in autism through the upregulation of oxidative and inflammatory mediators (36). We, therefore, speculated that the increased expression of IL-17B in the ASD group resulted from the induction of OPN, which caused oxidative damage and neuroinflammation. In addition, ASD was shown to be associated with increased expression of toll-like receptor (TLR) 4 on T cells (39). TLRs contribute to the pathogenesis of ASD by triggering NADPH oxidase (NOX)-2–derived ROS. In this study, TRIL was upregulated in the ASD group; we speculate that its activation enhances the production of NOX-2–derived ROS.

Tryptophan metabolism is linked to inflammation, the immune response, and oxidative stress in neurovascular diseases (40). We observed that tryptophan metabolism was markedly altered in ASD, consistent with previous studies (41–43) and supporting the role of tryptophan metabolism in neuroinflammation in ASD. Tryptophan can be metabolized in the intestine to form indole and its derivatives that act as aryl hydrocarbon receptor (AhR) ligands and are regulated by proteins in the cytochrome p450 family. The cytochrome P450 metabolic pathway is involved in the etiology of ASD and CYP1B1 is a potential biomarker of the disorder (44). The alteration in the cytochrome P450 metabolic pathway detected in our integrated analysis may lead to changes in AhR signaling, which may in turn cause dysregulation of tryptophan metabolism and neuroimmune dysfunction leading to ASD.

We observed that an integrated pathway related to immune response—namely, leukocyte transendothelial migration—was significantly enriched in the ASD group. Leukocyte transendothelial migration involves the spatiotemporal

---

TABLE 3 | The significantly enriched KEGG pathways of DEPs.

| Pathway name                        | Pathway ID | P-value | Level 1          | Level 2                      | Proteins                           |
|------------------------------------|------------|---------|------------------|-----------------------------|------------------------------------|
| Starch and sucrose metabolism      | ko00500    | 0.001   | Metabolism       | Carbohydrate metabolism     | AMY1A; AMY2A; GPI; AMY2B           |
| Carbohydrate digestion and absorption | ko04973    | 0.003   | Organismal Systems | Digestive system            | AMY1A; AMY2A; AMY2B               |
| Taste transduction                 | ko04742    | 0.006   | Organismal Systems | Sensory system              | GNS; SCNN1G                        |
| Glycosaminoglycan degradation      | ko00531    | 0.014   | Metabolism       | Glycan biosynthesis and metabolism | GNS; GALNS; NAGLU               |
| Leukocyte transendothelial migration | ko04670    | 0.032   | Organismal Systems | Immune system              | VCL; VCAM1; CDH5; VAV3            |
| Antigen processing and presentation | ko04612    | 0.032   | Organismal Systems | Immune system              | HLA-A; IFI30; AZGP1; B2M         |
| Graft-vs.-host disease             | ko05332    | 0.046   | Human Diseases   | Immune diseases             | HLA-A; AZGP1                      |
| Neuroactive ligand-receptor interaction | ko04080    | 0.048   | Environmental Information Processing | Signaling molecules and interaction | CALCA; AHSG; ADM         |
regulation of adhesion molecules, chemokines, and cytoskeletal regulators and is essential for the innate and adaptive immune responses (45). Four of the DEPs identified in our analysis were related to leukocyte transendothelial migration including vinculin, vascular cell adhesion protein (VCAM)1, cadherin (CDH)5, and guanine nucleotide exchange factor VAV3 isoform 1 (VAV3). Cell adhesion molecules (CAMs) have been implicated in impaired social interaction and communication and stereotyped and repetitive behaviors that characterize ASD (46–48). The protein levels of 5 other adhesion molecules including neuregulin (NRG)3, neural cell adhesion molecule (NCAM)1, CD166 antigen isoform 1 precursor (ALCAM1),
cadherin 16 isoform 1 precursor (CDH16), and macrophage migration inhibitory factor (MIF) were significantly altered in the ASD group compared with the TD group. MIF is an immunomodulatory cytokine that promotes inflammation and directional cell migration, inhibits apoptosis, induces the release of pro-inflammatory factors, and may contribute to ASD through the regulation of neuroinflammation (49). Plasma MIF concentration was found to be correlated with ASD severity and MIF may be a susceptibility gene in ASD (50). In addition, serum MIF levels were higher in patients with more severe ASD, and elevated MIF expression was positively correlated with ASD severity (51). In line with these earlier studies, we found that MIF expression was upregulated in children with ASD as compared with those with TD. Taken together, these data indicate that CAMs participate in the induction of neuroinflammation in ASD, although the significance of this effect on ASD development remains to be determined.

A total of 11 immunoglobulins showed significantly altered expression in the ASD group compared with the TD group, consistent with previous findings (52). Two of these immunoglobulins, HLA class I histocompatibility antigen (HLA-A) and zinc-alpha-2-glycoprotein precursor (AZGP1), are known to be involved in antigen processing and presentation, as well as graft-vs.-host disease and, are related

FIGURE 6 | The Venn diagram of the pathway in which differentially expressed proteins and metabolites were involved. (A) Differentially expressed proteins vs. metabolites in positive ion mode; (B) Differentially expressed proteins vs. metabolites in negative ion mode.
to neuroinflammation. HLA is the expression product of the major histocompatibility complex (MHC) and participates in the immune response by presenting peptides derived from the endoplasmic reticulum lumen (53). When the blood–brain barrier is damaged, it is penetrated by immune cells in the peripheral circulation and interacts with glial cells and neurons expressing MHC, resulting in the persistence of the immune response, interfering with the normal development of the nervous system, and leading to ASD.

Prostaglandin E2 (PGE2), an arachidonic acid metabolite of the cyclooxygenase (COX) signaling, is an endogenous lipid molecule that plays a key role during early nervous system development, and PGE2 signaling has been an important factor in the correlation between oxidative stress and ASD (54). Evidence from other studies suggested the link between irregular COX2/PGE2 signaling and autism-related behaviors (55). In addition, PGE2 plays a key role in inflammation in Alzheimer’s disease (AD) and shows increased expression in patients with AD compared with the normal subjects (56). In this study, we found that PGE2 was significantly upregulated in the ASD group by metabolomic analysis. Elevated PGE2 levels may also be linked to neuroinflammation in ASD.

**CONCLUSION**

We performed an integrated proteomic and metabolomic analysis to assess the role of neuroimmune responses in the development of ASD. Several metabolic pathways have been identified that may underlie ASD pathogenesis. As shown in Figure 8, oxidative stress may play a crucial role in the development of ASD by suppressing the protective effects of GSH, activating proinflammatory cytokines, and altering...
tryptophan metabolism. In addition, both the cell adhesion molecules and immunoglobulins can induce neuroinflammation in ASD. We also provide the first evidence of an association between PGE2 levels and inflammation in ASD. These results provide potential biomarkers that can be used for early ASD screening, risk stratification of patients with ASD, and the development of effective and targeted interventions.

DATA AVAILABILITY STATEMENT

The data presented in the study are deposited in the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the iProX partner repository (57), accession number PXD031652.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (Hubei, China). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

WL and JW designed the experiments and contributed to the critical revision of the article. WL analyzed and drafted the initial manuscript. WL, LL, and YD took part in the collection of urine samples. XX and JW participated in the proteomic analysis. XZ, ZY, and JW performed the metabolomic analysis. All authors contributed significantly to this work and have approved the final manuscript.

REFERENCES

1. Masi A, DeMayo MM, Glozier N, Guastella AJ. An overview of autism spectrum disorder, heterogeneity and treatment options. Neurosci Bull. (2017) 33:183–93. doi: 10.1007/s11224-017-0100-y
2. Matthew JM, Kelly AS, Jon B, Anita W, Mary P, Monica D, et al. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2016. MMWR Surveill Summ. (2020) 69:1–12. doi: 10.15585/mmwr.ss6904a1
3. Zhou H, Xu X, Yan W, Zou X, Wu L, Luo X, et al. Prevalence of autism spectrum disorder in China: a nationwide multi-center population-based study among children aged 6 to 12 years. Neurosci Bull. (2020) 36:961–71. doi: 10.1007/s11224-020-0570-0
4. Ravaccia D, Ghafourian T. Critical role of the maternal immune system in the pathogenesis of autism spectrum disorder. Biomedicines. (2020) 8:557. doi: 10.3390/biomedicines8120557
5. Meltzer A, Van de Wate J. The role of the immune system in autism spectrum disorder. Front Neurol. (2020) 11:551587. doi: 10.3389/fneur.2020.551587

FUNDING

This work was supported by the National Natural Science Foundation of China (No. 81960290), the Natural Science Foundation of Fujian Province of China (No. 2021J01345), the Scientific and Technological Plan Projects of Xiamen (No. 3502Z20159004), and the Foundation of Xiamen Medical College (Nos. K2016-11 and K2020-01).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2022.780747/full#supplementary-material

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomcentral.proteomexchange.org) via the iProX partner repository (57) with the dataset identifier PXD031652.

**Supplementary Figure 1** | Identification of DEPs. The X-axis represents protein difference (log2-transformed fold changes), and the Y-axis the corresponding -log10-transformed P-values. Red dots indicate significantly upregulated proteins, green dots indicate significantly downregulated proteins, and gray dots indicate no significant change.

**Supplementary Figure 2** | Total ion chromatogram of a urine sample. (A) positive ion mode; (B) negative ion mode.

**Supplementary Figure 3** | The QC analysis of the proteome. (A) within-group coefficient of variation; (B) Principal Component Analysis (PCA).

**Supplementary Table 1** | The significantly enriched terms in the biological process.

**Supplementary Table 2** | The top 10 different metabolites in positive ion mode.

**Supplementary Table 3** | The top 10 different metabolites in negative ion mode.
and prostaglandin E2 synthesis in a mouse model of idiopathic autism. J Neuroinflammation. (2016) 13:149. doi: 10.1186/s12974-016-0617-4
55. Wong CT, Bestard-Lorigados I, Crawford DA. Autism-related behaviors in the cyclooxygenase-2-deficient mouse model. Genes Brain Behav. (2019) 18:e12506. doi: 10.1111/gbb.12506
56. Montine TJ, Sidell KR, Crews BC, Marquesbery WR, Marnett LJ, Roberts LJ, et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology. (1999) 53:1495–8. doi: 10.1212/WNL.53.7.1495
57. Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome resource. Nucleic Acids Res. (2019) 47:D1211–7. doi: 10.1093/nar/gky869

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liu, Li, Xia, Zhou, Du, Yin and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.